Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Minocycline in phenotypic models of Huntington's disease.

Neurobiology of disease - 1 Feb 2005

Bantubungi Kadiombo, Jacquard Carine, Greco Anita, Pintor Annita, Chtarto Abdelwahed, Tai Khalid, Galas Marie-Christine, Tenenbaum Liliane, Déglon Nicole, Popoli Patrizia, Minghetti Luisa, Brouillet Emmanuel, Brotchi Jacques, Levivier Marc, Schiffmann Serge N, Blum David

Abstract excerpt

Minocycline has been shown to be neuroprotective in various models of neurodegenerative diseases. However, its potential in Huntington's disease (HD) models characterized by calpain-dependent degeneration and inflammation has not been investigated. Here, we have tested minocycline in phenotypic models of HD using 3-nitropropionic acid (3NP) intoxication and quinolinic acid (QA) injections. In the 3NP rat model,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calpain
Share to Encephalitis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Minocycline

Share to Neuroprotective Agents

Share to Nitro Compounds

Share to Propionates

Share to Rats, Inbred Lew

Share to Staurosporine

Source

Identifiers

PMID: 15649711
DOI: 10.1016/j.nbd.2004.09.017

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Minocycline in phenotypic models of Huntington's disease.PMID 15649711Read ↗

Minocycline for Huntington’s disease: An open label studySemantic proximity Read ↗

Minocycline and doxycycline are not beneficial in a model of Huntington's disease.Semantic proximity Read ↗

3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease.Semantic proximity Read ↗

Minocycline Attenuates Neuronal Cell Death and Improves Cognitive Impairment in Alzheimer's Disease ModelsSemantic proximity Read ↗

Minocycline as a potential therapeutic agent in neurodegenerative disorders characterized by protein misfoldingSemantic proximity Read ↗

Lack of minocycline efficiency in genetic models of Huntington's disease.Semantic proximity Read ↗

Minocycline inhibits cell death and decreases mutant Huntingtin aggregation by targeting Apaf-1.Semantic proximity Read ↗

Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype.Semantic proximity Read ↗

Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline.Semantic proximity Read ↗

Can minocycline prevent the onset of Alzheimer's disease?Semantic proximity Read ↗

Minocycline inhibition of microglial rescues nigrostriatal dopaminergic neurodegeneration caused by mutant alpha-synuclein overexpression.Semantic proximity Read ↗

Mice transgenic for the Huntington's disease mutation are resistant to chronic 3-nitropropionic acid-induced striatal toxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.